Abstract
Quality of life (QL) is an important consideration when comparing adjuvant therapies for early breast cancer, especially if they differ substantially in toxicity. We evaluated QL and Q-TWiST among patients randomised to adjuvant dose-intensive epirubicin and cyclophosphamide administered with filgrastim and progenitor cell support (DI-EC) or standard-dose anthracycline-based chemotherapy (SD-CT). We estimated the duration of chemotherapy toxicity (TOX), time without disease symptoms and toxicity (TWiST), and time following relapse (REL). Patients scored QL indicators. Mean durations for the three transition times were weighted with patient reported utilities to obtain mean Q-TWiST. Patients receiving DI-EC reported worse QL during TOX, especially treatment burden (month 3: P
Original language | English |
---|---|
Pages (from-to) | 25-33 |
Number of pages | 9 |
Journal | British Journal of Cancer |
Volume | 98 |
Issue number | 1 |
DOIs | |
Publication status | Published - Jan 15 2008 |
Keywords
- Adaptation
- Adjuvant chemotherapy
- Breast cancer
- Quality of life
- Quality-adjusted survival
ASJC Scopus subject areas
- Cancer Research
- Oncology